Virax Biolabs

Home
United Kingdom
London
Virax Biolabs

Biotechnology company focused on detection of immune responses to & diagnosis of viral diseases

Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.

26/05/2026

Today marks an important milestone for Virax Biolabs.

We are excited to announce positive early pilot results for ViraxImmune™, our blood-based test designed to identify Long COVID and related post-acute infection syndromes (PAIS).

With millions of people globally facing lengthy, symptom-based diagnostic journeys, the need for objective immune biomarkers has never been more urgent. In our pilot dataset, ViraxImmune™ demonstrated encouraging separation between PAIS patients and healthy controls, achieving 88% specificity and a 92% positive predictive value.

This is a promising step forward as we prepare for a larger clinical validation study later this year and map out our U.S. market-entry strategy.

Read the full press release and dive into the data, milestones, and details about our investor webcast happening today: https://ir.viraxbiolabs.com/news-events/press-releases/detail/81/virax-biolabs-reports-positive-early-clinical-data-for

21/05/2026

Hello from SLAS Europe 2026!

If you’re attending, find us at Booth 111 to chat about your upcoming projects and how we can support your workflows.

Our team is on hand to talk through our research portfolio, including ImmuneSelect peptide pools and ELISpot solutions, and to explore how our custom immunology services can fit into your specific research needs.

📍 Where: Booth 111
🗓️ When: 19–21 May 2026 (and we’re still here!)

Swing by and say hello to Esra Güç and Ufuk Bikez at the booth—we’d love to connect.

18/05/2026

Virax Biolabs Expands Ebola Immunology Portfolio Amid Global Health Emergency

The WHO's declaration of a global health emergency around the Bundibugyo Ebola strain outbreak has intensified demand for vaccine and therapeutic development tools. Virax Biolabs is actively supporting this need.

Our ImmuneSelect Ebola Zaire peptide pool is commercially available; a research-grade immunology tool for vaccine developers and diagnostic innovators. With Bundibugyo emerging as a novel threat with no approved vaccines or therapeutics, we are developing an ImmuneSelect Ebola Bundibugyo peptide pool to support pandemic response efforts.

Vaccine developers, therapeutic manufacturers, and diagnostic innovators requiring strain-specific immunology tools are invited to discuss partnership and bulk supply arrangements.

13/05/2026

We are heading to Vienna!

Virax Biolabs is excited to announce our participation in SLAS Europe 2026. Stop by booth 111 to chat about your upcoming projects.

Our team will be on hand to discuss our research portfolio, including our ImmuneSelect peptide pools and ELISpot solutions. It is also a great chance to look at our custom immunology services and see how they fit into your specific workflows.

Where: Booth 111
When: 19–21 May 2026

See you there!

07/05/2026

Have you explored the new home of Virax Biolabs research yet?

One month ago, we launched research.viraxbiolabs.com, and the response from the immunology community has been incredible.

Whether you’re looking for high-sensitivity ELISpot kits, peptide pools for T cell stimulation, or custom lab services, our dedicated RUO hub is designed to get you the tools you need, faster.

Watch the video for a quick tour and stop by to see what’s new: https://research.viraxbiolabs.com/

14/04/2026

The Virax Biolabs Q2 2026 update is here.

We’ve just released our latest Investor Presentation, detailing our recent clinical milestones and strategic roadmap. In addition, our CEO James Foster, outlines our strategic and commercial framework in his latest letter to shareholders.

Together, they map out where we’re headed as we tackle the massive, underserved challenge of post-acute infection syndromes (PAIS), including Long COVID and ME/CFS.

Want to learn more?

View the Q2 2026 Investor Presentation here: https://diagnostics.viraxbiolabs.com/virax-biolabs-q2-2026-investor-presentation/

Read the full CEO Letter here: https://ir.viraxbiolabs.com/news-events/press-releases/detail/80/virax-biolabs-ceo-james-foster-outlines-strategic

08/04/2026

Research has a new home at Virax Biolabs.

We’ve just launched research.viraxbiolabs.com – our dedicated hub for RUO products and immunology research solutions.

Explore our ImmuneSelect portfolio, featuring:
- Peptide pools for T cell activation
- High-sensitivity ELISpot kits
- Recombinant antibodies & custom lab services

Check out the full catalogue and see how we’re supporting the next wave of immune research.

25/02/2026

Recent CDC and NCHS Household Pulse Survey data indicates that roughly 14 to 17 million adults in the U.S. are currently affected by Long COVID, with roughly 25% of these individuals experiencing significant limitations in their daily activities due to the condition.
With millions of lives impacted, these figures highlight a pressing need for post-acute infection research and diagnostics. By finding more effective ways to diagnose these diseases and understanding their underlying mechanisms, we can work toward a more consistent standard of care for everyone affected.

Learn more about the latest estimates from the Household Pulse Survey: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm

Learn more about the development of our novel diagnostic ViraxImmune™: https://viraxbiolabs.com/viraximmune/

17/02/2026

Happy Lunar New Year from the team at Virax Biolabs!

We're channeling the energy and momentum of the Year of the Horse into a year of growth and new milestones. Wishing all our friends, partners and customers a happy and prosperous year ahead.

17/03/2025

CLP Magagazine's latest article dives into the data presented by Virax Biolabs at the 19th World Immune Regulation Meeting in Davos, Switzerland. The study highlights how T cell exhaustion markers impact post-acute infection syndromes (PAIS) like long COVID, ME/CFS, and chronic Lyme disease.

Don’t miss it - read the full article now at: https://clpmag.com/diagnostic-technologies/immunoassay/t-cell-dysfunction-in-post-acute-infection-syndromes-presented/

Address

London

Telephone

+442077887414

Website

https://www.viraxbiolabs.com/

Alerts

Be the first to know and let us send you an email when Virax Biolabs posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Health & Beauty Business in London?